Effects of Rotigaptide, a gap junction modifier, on defibrillation energy and resuscitation from cardiac arrest in rabbits

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 12, Issue 1, 2007, Pages 69-77

  Zhong, Jing Quan ^a,b   Laurent, Gabriel ^a,b   So, Petsy Pui Sze ^a,b   Hu, Xudong ^a,b   Hennan, James K ^c   Dorian, Paul ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c PFIZER INC   (United States)

Author keywords

Connexin 43; Defibrillation; Gap junctions; Ventricular fibrillation

Indexed keywords

CONNEXIN 43; ROTIGAPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DEFIBRILLATION; DRUG EFFECT; HEART ARREST; HEART MUSCLE POTENTIAL; HEART RATE; HEART VENTRICLE FIBRILLATION; IMMUNOFLUORESCENCE; LOADING DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RABBIT; RANDOMIZATION; RESUSCITATION;

ACTION POTENTIALS; ANIMALS; BLOOD PRESSURE; CONNEXIN 43; DISEASE MODELS, ANIMAL; ELECTRIC COUNTERSHOCK; ELECTRIC STIMULATION; ELECTROCARDIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE; GAP JUNCTIONS; HEART ARREST; HEART RATE; INJECTIONS, INTRAVENOUS; MALE; MYOCYTES, CARDIAC; OLIGOPEPTIDES; RABBITS; RANDOM ALLOCATION; RESUSCITATION; VENTRICULAR FIBRILLATION;

EID: 34247585484     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406298021     Document Type: Article

References (34)

1. Zipes DP, Wellens HJ Sudden cardiac death. Circulation. 1998 ; 98: 2334-2351.
2. Gliner BE, White RD Electrocardiographic evaluation of defibrillation shocks delivered to out-of-hospital sudden cardiac arrest patients. Resuscitation. 1999 ; 41: 133-144.
3. Menegazzi JJ, Callaway CW, Sherman LD, et al. Ventricular fibrillation scaling exponent can guide timing of defibrillation and other therapies. Circulation. 2004 ; 109: 926-931.
4. Dorian P., Cass D., Schwartz B., Cooper R., Gelaznikas R., Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002 ; 346: 884-890.
5. Dorian P., Fain ES, Davy JM, Winkle RA Lidocaine causes a reversible concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol. 1986 ; 8: 327-332.
6. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999 ; 341: 871-878.
7. De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res. 2004 ; 62: 323-334.
8. Van Rijen H., De Bakker J., Van Veen T. Hypoxia, electrical uncoupling, and conduction slowing: Role of conduction reserve. Cardiovas Res. 2005 ; 66: 9-11.
9. Myerburg RJ, Kessler KM, Interian A. Jr, et al. Clinical and experimental pathophysiology of sudden cardiac death. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside, 1 st ed. Philadelphia, Pa: WB Saunders Co, 1990: 666-678.
10. Dorian P., Wang M., David I., Feindel C. Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation. 1991 ; 83: 614-621.
11. Labhasetwar V., Underwood T., Heil RW Jr, Gallagher M., Langberg J., Levy RJ Epicardial administration of ibutilide from polyurethane matrices: effects on defibrillation threshold and electrophysiologic parameters. J Cardiovasc Pharmacol. 1994 ; 24: 826-840.
12. Qi XQ, Newman D., Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Interv Card Electrophysiol. 1999 ; 3: 61-67.
13. Xing D., Kjlbye AL, Nielsen MS, et al. Rotigaptide increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol. 2003 ; 14: 510-520.
14. Eloff BC, Gilat E., Wan X., Rosenbaum DS Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation. 2003 ; 108: 3157-3163.
15. Haugan K., Olsen KB, Hartvig L., et al. The antiarrhythmic peptide analogue rotigaptide prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol. 2005 ; 16: 1-9.
16. Pogwizd SM Prevention of ischemia-induced reentrant ventricular arrhythmias by a peptide that enhances gap junctional conductance. J Cardiovasc Electrophysiol. 2003 ; 14: 521-523.
17. Qin H., Walcott GP, Killingsworth CR, Rollins DL, Smith WM, Ideker RE Impact of myocardial ischemia and reperfusion on ventricular defibrillation patterns, energy requirements, and detection of recovery. Circulation. 2002 ; 105: 2537-2542.
18. Dhein S., Manicone N., Muller A., Gerwin R., Ziskoven U., Irankhahi A., et al. A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn Schmiedebergs Arch Pharmacol. 1994 ; 350: 174-184.
19. Kjlbye AL, Knudsen CB, Jepsen T., Larsen BD, Petersen JS Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies. J Pharmacol Exp Ther. 2003 ; 306: 1191-1199.
20. Sims JJ, Schoff KL, Loeb JM, Wiegert NA Regional gap junction inhibition increases defibrillation thresholds. Am J Physiol Heart Circ Physiol. 2003 ; 285: H10 - H16.
21. Qi X., Varma P., Newman D., Dorian P. Gap junction blockers decrease defibrillation thresholds without changes in ventricular refractoriness in isolated rabbit hearts. Circulation. 2001 ; 104: 1544-1549.
22. Xing D., Kjlbye AL, Petersen JS, Martins JB Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia-induced focal ventricular tachycardia or triggered activity in dogs. Am J Physiol Heart Circ Physiol. 2005 ; 288: H511-516.
23. Peters NS, Coromillas J., Severs NJ, Wit AL Disturbed connexin 43 gap junction distribution correlates with the location of re-entrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation. 1997 ; 95: 988-996.
24. Hennan JK, Swillo RE, Morgan GA, et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/ reperfusion injury in open-chest dogs. J Pharmacol Exp Ther. 2006 ; 317 (1). 236-243.
25. Haugan K., Miyamoto T., Takeishi Y., Kubota I., Nakayama J., Shimojo H., Hirose M. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload induced dilated atria. Basic Clin Pharmacol Toxicol. 2006 ; 99 (1). 71-79.
26. Beardslee MA, Lerner DL, Tadros PN, et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res. 2000 ; 87 (8). 656-662.
27. Yaku H., Goto Y., Ohgoshi Y., Kawaguchi O., Oga K., Oka T., et al. Determinants of myocardial oxygen consumption in fibrillating dog hearts. Comparison between normothermia and hypothermia. J Thorac Cardiovasc Surg. 1993 ; 105: 679-688.
28. Xing D., Kjolbye AL, Nielsen MS, et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol. 2003 ; 14 (5). 510-520.
29. Guerra JM, Everett TH 4th, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation. 2006 ; 114 (2). 110-118.
30. Clarke TC, Thomas D., Petersen JS, Evans WH, Martin PE The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol. 2006 ; 147 (5). 486-495.
31. Chattipakorn N., Ideker RE Delayed afterdepolarization inhibitor: A potential pharmacologic intervention to improve defibrillation efficacy. J Cardiovasc Electrophysiol. 2003 ; 14: 72-75.
32. Dekker LR, Rademaker H., Vermeulen JT, Opthof T., Coronel R., Spaan JA, Janse MJ Cellular uncoupling during ischemia in hypertrophied and failing rabbit ventricular myocardium: effects of preconditioning. Circulation. 1998 ; 97: 1724-1730.
33. Dhein S., Larsen BD, Petersen JS, Mohr FW Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern. Cell Commun Adhes. 2003 ; 10: 371-378.
34. Watson CL, Gold MR Modulation of Na+ current inactivation by stimulation of protein kinase C in cardiac cells. Circ Res. 1997 ; 81: 380-386.